CIDRAP Developing R&D Roadmap for Coronavirus Vaccines

Friday, October 21, 2022

COVID-19 and its impacts have dominated the public health landscape since its emergence in late 2019.  The novel pathogen that causes COVID-19 (SARS-CoV-2) is not the only coronavirus to impact humans in recent years, and likely won’t be the last. In a commentary published in the journal Vaccine, experts from the Center for Infectious Disease Research and Policy (CIDRAP) and the Mayo Clinic discuss current coronavirus vaccine limitations, as well as the challenges of developing improved coronavirus vaccines. They also announce CIDRAP’s efforts to establish an R&D roadmap for creating vaccines that will be broadly protective against coronaviruses. The roadmap will be open for public comment between October 24 and November 18, and finalized in early 2023. Lead author, Kristine Moore, is the Medical Director for CIDRAP; CIDRAP Director Michael Osterholm, CIDRAP Deputy Director Eve Lackritz, and Gregory Poland of the Mayo Vaccine Research Group are also authors. CIDRAP is a Consortium member center. Read the article in Vaccine.